Abstract: A composition including a strain of Lactobacillus salivarius SA-03 has at least one of the physiologically active effects of anti-oxidation, oral health, immunity regulation, and promotion of exercise. Therefore, the above-mentioned composition can be used for the foregoing physiological activity and is used in a form of food, medicine, and oral cleaning composition.

Abstract: Disclosed herein is a method for alleviating an inflammation-related disorder, which includes administering to a subject in need thereof a composition containing a culture of at least one lactic acid bacterial strain. The at least one lactic acid bacterial strain is selected from the group consisting of Lactobacillus plantarum LPL28 which is deposited at the China General Microbiological Culture Collection Center (CGMCC) under an accession number CGMCC 17954, Bifidobacterium animalis subsp. lactis CP-9 which is deposited at the China Center for Type Culture Collection (CCTCC) under an accession number CCTCC M 2014588, and Bifidobacterium longum subsp. longum OLP-01 which is deposited at the CGMCC under an accession number CGMCC 17345.

Abstract: At least one isolated lactic acid bacteria strains selected from the following: TSP05 (Lactobacillus plantarum), TSF331 (Lactobacillus fermentum) and TSR332 (Lactobacillus reuteri) is provided. The above-mentioned active or inactive lactic acid bacteria strains have a function of hepatoprotection and is used in a form of a food composition or a pharmaceutical composition.

Abstract: An isolated lactic acid bacteria strain: Bifidobacterium longum subsp. longum OLP-01 strain for increasing exercise performance and ameliorating fatigue is disclosed. A variety of animal experiments have proved that OLP-01 not only effectively improves muscle strength and swimming endurance but also significantly reduces fatigue-related biochemical indicators, including blood lactate, blood urea nitrogen and the activity of creatine kinase.

Abstract: The present invention provides a lactobacillus strain-containing pharmaceutical composition and food composition for improving of kidney disease and inhibiting inflammation, which comprises an isolated lactic acid bacteria strain. The isolated lactic acid bacteria strain is at least one selected from a group including BLI-02 strain, CGMCC No. 15212, Bifidobacterium longum subsp. infantis, TYCA06 strain, CGMCC No. 15210, Lactobacillus acidophilus, VDD088 strain, CGMCC No. 15211, Bifidobacterium bifidum, and combinations thereof.

Abstract: A vaginitis pathogen-inhibiting composition comprises a fermentate of lactic acid bacteria, which is generated by jointly fermenting a lactic acid bacteria strain and Streptococcus thermophilus in a medium containing at least one of milk, powdered milk, and casein. The lactic acid bacteria strain includes an AP-32 strain of Lactobacillus salivarius subsp. Salicinius; an F-1 strain of Lactobacillus rhamnosus; a GL-165 strain of Lactobacillus rhamnosus; a CP-9 strain of Bifidobacterium animalis subsp. lactis; a Bf-688 strain of Bifidobacterium bifidum; a Bv-889 strain of Bifidobacterium breve; or combinations thereof. The above-mentioned fermentate of the lactic acid bacteria strain can inhibit growth of vaginitis pathogens and may be in form of a food composition, a pharmaceutical composition, or a vagina-cleaning composition.

Abstract: An isolated lactic acid bacterium strain or fermentation metabolite thereof has an anti-oxidant function and is in form of a food composition or a pharmaceutical composition, wherein the isolated lactic acid bacterium strain comprises at least one of an OLP-01 strain of Bifidobacterium longum subsp. longum; a Bv-889 strain of Bifidobacterium breve; a BLI-02 strain of Bifidobacterium longum subsp. infantis; a CP-9 strain of Bifidobacterium animalis subsp. lactis; a Bf-688 strain of Bifidobacterium bifidum; a GL-104 strain of Lactobacillus reuteri; an AP-32 strain of Lactobacillus salivarius subsp. salicinius; and a bv-77 strain of Lactobacillus rhamnosus.

Abstract: A fermentation metabolite generated by an isolated lactic acid bacterium including at least one of a Bv-889 strain of Bifidobacterium breve, a BLI-02 strain of Bifidobacterium longum subsp. infantis, a CP-9 strain of Bifidobacterium animalis subsp. lactis, a Bf-688 strain of Bifidobacterium bifidum, an AP-32 strain of Lactobacillus salivarius subsp. salicinius, and a GL-156 strain of Lactobacillus paracasei. The fermentation metabolite of the abovementioned strains have a skin-whitening effect and is in form of a food composition or a cosmeceutical composition.

Abstract: A food composition and pharmaceutical composition with strains of lactic acid bacteria for modulating blood glucose are provided, comprising an isolated lactic acid bacteria strain. The isolated lactic acid bacteria strain is at least one selected from a group including a GL-104 strain of Lactobacillus reuteri (CCTCC NO: M209138), an AP-32 strain of Lactobacillus salivarius subsp. salicinius (CCTCC NO: M2011127), a TYCA06 strain of Lactobacillus acidophilus (CGMCC No: 15210), and an MH-68 strain of Lactobacillus johnsonii (CCTCC NO: M2011128), or a combination thereof.

Abstract: An isolated lactic acid bacteria strain: Bifidobacterium longum subsp. longum OLP-01 strain for increasing exercise performance and ameliorating fatigue is disclosed. A variety of animal experiments have proved that OLP-01 not only effectively improves muscle strength and swimming endurance but also significantly reduces fatigue-related biochemical indicators, including blood lactate, blood urea nitrogen and the activity of creatine kinase.

Abstract: At least one isolated lactic acid bacteria strains selected from the following: TSP05 (Lactobacillus plantarum), TSF331 (Lactobacillus fermentum) and TSR332 (Lactobacillus reuteri) is provided. The above-mentioned active or inactive lactic acid bacteria strains have a function of hepatoprotection and is used in a form of a food composition or a pharmaceutical composition.

Abstract: A food composition and pharmaceutical composition with strains of lactic acid bacteria for reducing blood uric acid concentration are provided, comprising at least one or two isolated lactic acid bacteria strains selected from the following two: TSF331 (Lactobacillus fermentum) and TSR332 (Lactobacillus reuteri).

Abstract: A method of inhibiting oral pathogens comprising administering to a subject in need thereof an effective amount of lactobacillus strain-containing food composite, medical composite and oral cleaning composite. The food composite, medical composite and oral cleaning composite comprises at least one lactobacillus strain, which is at least one isolated lactobacillus strain selected from a group including Lactobacillus acidophilus F-1 strain, CCTCC NO: M2011124; Lactobacillus salivarius subsp. salicinius AP-32 strain, CCTCC NO: M2011127; Lactobacillus reuteri GL-104 strain, CCTCC NO: M209138; Lactobacillus paracasei GL-156 strain, CCTCC NO: M2014590; Lactobacillus helveticus RE-78 strain, CGMCC No. 13513; Lactobacillus rhamnosus CT-53 strain, CCTCC NO: M2011129; and Lactobacillus paracasei ET-66 strain, CGMCC No. 13514, which are respectively preserved in China Center for Type Culture Collection (CCTCC) and China General Microbiological Culture Collection Center (CGMCC).

Abstract: The present invention provides a lactobacillus strain-containing pharmaceutical composition and food composition for improving of kidney disease and inhibiting inflammation, which comprises an isolated lactic acid bacteria strain. The isolated lactic acid bacteria strain is at least one selected from a group including BLI-02 strain, CGMCC No. 15212, Bifidobacterium longum subsp. infantis, TYCA06 strain, CGMCC No. 15210, Lactobacillus acidophilus, VDD088 strain, CGMCC No. 15211, Bifidobacterium bifidum, and combinations thereof.

Abstract: A food composite, an oral cleaning composite or a medical composite contain at least one lactobacillus strain able to inhibit oral pathogens. The lactobacillus strain is at least one isolated lactobacillus strain selected from a group including Lactobacillus acidophilus F-1 strain; Lactobacillus salivarius subsp. salicinius AP-32 strain; Lactobacillus reuteri GL-104 strain; Lactobacillus paracasei GL-156 strain; Lactobacillus helveticus RE-78 strain; Lactobacillus rhamnosus CT-53 strain; and Lactobacillus paracasei ET-66 strain. The abovementioned lactobacillus strains are able to inhibit oral pathogens and carried by a food composite, an oral cleaning composite or a medical composite.